Trifarotene: A Novel Therapeutic Option for Acne
Acne vulgaris, or acne, is a prevailing cutaneous predicament that customarily crops up on the face, neck, and trunk in the forms of comedones, papules, pustules, and nodules. According to epidemiologic explorations, acne affects 9.4% of the global population, making it the eighth most common diseas...
Saved in:
| Main Author: | |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2022-01-01
|
| Series: | Dermatology Research and Practice |
| Online Access: | http://dx.doi.org/10.1155/2022/1504303 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849411564211273728 |
|---|---|
| author | Piyu Parth Naik |
| author_facet | Piyu Parth Naik |
| author_sort | Piyu Parth Naik |
| collection | DOAJ |
| description | Acne vulgaris, or acne, is a prevailing cutaneous predicament that customarily crops up on the face, neck, and trunk in the forms of comedones, papules, pustules, and nodules. According to epidemiologic explorations, acne affects 9.4% of the global population, making it the eighth most common disease globally. Acne perturbs up to 85% of adolescents, while it is periodically misconceived as an ailment that affects teenagers only; nonetheless, it also affects myriad adults. Acne has well-documented psychosocial ramifications, including adverse effects on self-perception, mental health, and social functioning. Trifarotene is basically a novel fourth-generation locally applied retinoid approved for the first time in the regimens of both face and truncal acnes. The exclusive topical retinoid that adheres precisely to RAR-gamma, the epidermis' most frequent isoform, is trifarotene, approved in October 2019. The current review evaluates the role of trifarotene in treating acne. |
| format | Article |
| id | doaj-art-5de3a4a77a6e4d9aaf1f39f4f184fe71 |
| institution | Kabale University |
| issn | 1687-6113 |
| language | English |
| publishDate | 2022-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | Dermatology Research and Practice |
| spelling | doaj-art-5de3a4a77a6e4d9aaf1f39f4f184fe712025-08-20T03:34:44ZengWileyDermatology Research and Practice1687-61132022-01-01202210.1155/2022/1504303Trifarotene: A Novel Therapeutic Option for AcnePiyu Parth Naik0Department of dermatologyAcne vulgaris, or acne, is a prevailing cutaneous predicament that customarily crops up on the face, neck, and trunk in the forms of comedones, papules, pustules, and nodules. According to epidemiologic explorations, acne affects 9.4% of the global population, making it the eighth most common disease globally. Acne perturbs up to 85% of adolescents, while it is periodically misconceived as an ailment that affects teenagers only; nonetheless, it also affects myriad adults. Acne has well-documented psychosocial ramifications, including adverse effects on self-perception, mental health, and social functioning. Trifarotene is basically a novel fourth-generation locally applied retinoid approved for the first time in the regimens of both face and truncal acnes. The exclusive topical retinoid that adheres precisely to RAR-gamma, the epidermis' most frequent isoform, is trifarotene, approved in October 2019. The current review evaluates the role of trifarotene in treating acne.http://dx.doi.org/10.1155/2022/1504303 |
| spellingShingle | Piyu Parth Naik Trifarotene: A Novel Therapeutic Option for Acne Dermatology Research and Practice |
| title | Trifarotene: A Novel Therapeutic Option for Acne |
| title_full | Trifarotene: A Novel Therapeutic Option for Acne |
| title_fullStr | Trifarotene: A Novel Therapeutic Option for Acne |
| title_full_unstemmed | Trifarotene: A Novel Therapeutic Option for Acne |
| title_short | Trifarotene: A Novel Therapeutic Option for Acne |
| title_sort | trifarotene a novel therapeutic option for acne |
| url | http://dx.doi.org/10.1155/2022/1504303 |
| work_keys_str_mv | AT piyuparthnaik trifaroteneanoveltherapeuticoptionforacne |